About R3 Bio

Leadership

R3 Bio is built as a focused, interdisciplinary team combining scientific leadership, operational execution, and external strategic support. Our structure is designed to move early-stage research forward with rigor, flexibility, and disciplined prioritization.

John Schloendorn, PhD

CEO / CSO

Alice Gilman

COO / CoS

John Schloendorn, PhD has 20 years experience founding and leading projects and companies in bioproduction, regenerative medicine, and longevity. John is the principal investigator of the project. He co-invented much of our technology and coordinates the scientific team, and grounds company strategy in scientific reality.

Alice Gilman is Chief Operating Officer of R3 Bio, where she leads operational infrastructure, investor engagement, and cross-border execution. Her experience spans logistics, field coordination, and complex program operations across more than 30 countries, including multi-site initiatives in challenging environments. At R3 Bio, she focuses on building the organizational systems, external relationships, and execution capacity needed to advance ambitious scientific programs responsibly and efficiently.

The rest of the team is not currently public

How Better Science Happens

A staged, validation-oriented approach to developing better stem-cell-based research models.

Design Bio Systems

We develop stem-cell-based in vitro systems using cellular reprogramming, stem-cell-derived biology, and other model-building approaches.

Replace Where Appropriate

New Approach Methodologies are deployed to reduce reliance on animal testing while maintaining scientific rigor.

Generate Predictive Data

High-throughput experimentation and intelligent analytics surface translational signals earlier in development.

Enable Confident Decisions

Validated, regulator-aligned outputs help partners advance the right programs faster— and stop weak candidates sooner.